RxDoctor Payments Data

Stephen To, MD

Family Medicine · Chesapeake, VANPI 1790992709

Payments from drug & device makers

$6,678in general payments, 2019–2025

Across 403 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$991
  • Novo Nordisk$949
  • AstraZeneca$492
  • Lilly USA, LLC$481
  • Merck$340
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$6,63399%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,678 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$172,452
Medicare patients
463
Services billed
2,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$98,829
EliquisApixaban46$59,167
XifaxanRifaximin12$40,487
JanuviaSitagliptin Phosphate26$30,123
FarxigaDapagliflozin Propanediol21$25,218
JardianceEmpagliflozin30$24,925
Synjardy XrEmpagliflozin/Metformin Hcl25$22,107
Janumet XrSitagliptin Phos/Metformin Hcl14$18,339
MounjaroTirzepatide13$14,287
TrulicityDulaglutide12$10,086
DayvigoLemborexant15$4,952
Rosuvastatin Calcium233$3,420
Atorvastatin Calcium307$2,911
Tolterodine Tartrate ErTolterodine Tartrate14$2,874
Pregabalin23$2,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$949$98,82963 claims
PfizerEliquis$991$59,16746 claims
MerckJanuvia, Janumet Xr$340$48,46240 claims
Boehringer IngelheimJardiance, Synjardy Xr$166$47,03255 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$182$40,48712 claims
AstraZenecaFarxiga$492$25,21821 claims
Lilly USA, LLCMounjaro, Trulicity$481$24,37325 claims
Eisai Inc.Dayvigo$25$4,95215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →